Rare disease clinical trials present a distinct set of challenges that make sourcing strategies critical to study success. With fewer patients, limited historical data and small global treatment populations, every component of the trial must be executed with precision, especially the sourcing of comparator drugs and ancillary supplies. In rare disease studies patient recruitment is already difficult. Delays due to drug unavailability or supply chain inefficiencies can have a